GSK to Acquire RAPT in $2.2 Billion Deal, Adding Late-Stage Anti-IgE Candidate Ozureprubart for Food Allergy and Chronic Spontaneous Urticaria | iPharmaCenter

GSK has entered into a definitive agreement to acquire RAPT Therapeutics, expanding its Respiratory, Immunology & Inflammation pipeline with a late-stage, long-acting anti-IgE antibody for food allergies.

The transaction is valued at approximately 2.2 billion dollars in equity and is expected to close in the first quarter of 2026, subject to customary regulatory approvals.

Through this acquisition, GSK will gain global rights to ozureprubart, a next-generation, long-acting monoclonal antibody targeting immunoglobulin E (IgE), currently in phase 2b clinical development for the prophylactic prevention of food allergy reactions.

Under the terms of the agreement, GSK will launch a cash tender offer to acquire all outstanding shares of RAPT common stock for 58.00 dollars per share. This represents an approximate equity value of 2.2 billion dollars; after accounting for cash on RAPT’s balance sheet, GSK’s estimated upfront investment is around 1.9 billion dollars.

Existing systemic anti‑IgE treatment for food allergy typically requires injections every two to four weeks, which can be particularly challenging for families and caregivers, as most patients are children or adolescents.

Ozureprubart is currently being evaluated in phase 2 clinical studies for both IgE‑mediated food allergies and chronic spontaneous urticaria.

Ozureprubart has been engineered to provide prolonged suppression of free IgE, allowing dosing as infrequently as every 12 weeks. This extended dosing interval offers the potential to ease treatment burden, support adherence and improve outcomes for people living with serious food allergies.